tirzepatide and vision issues Comparative ocular outcomes of versus other anti-obesity medications in people with obesity RACGP - Semaglutide links to

The study titled Off-label antiobesity treatment in patients without diabetes with GLP-1 agonists in clinical practice and published in Hormone and Metabolic Research indicates that 58% of patients reported side effects mostly concerning the gastrointestinal tract. In addition, more than 20% of the participants quit the drug because of intolerable side effects. This study certainly put Novo Nordisk on risk of bowel injuries associated with the use of Ozempic

Tirzepatide trials consistently demonstrate substantial weight loss and improvements in cardiometabolic markers

Your provider may recommend a temporary dose pause or adjustment to establish better tolerability before advancing

Your plan should be based on your labs, medical history, current medications, and personal goals

Fortino and his team before starting any new supplement or treatment to ensure it complements your Tirzepatide weight loss program